Biomarkers for early diagnosis of pancreatic cancer.
Pancreatic ductal adenocarcinoma is an aggressive malignancy with a 5-year survival rate of approximately 5%. The lack of established strategies for early detection contributes to this poor prognosis. Although several novel candidate biomarkers have been proposed for earlier diagnosis, none have been adopted into routine clinical use. In this review, the authors examine the challenges associated with finding new pancreatic cancer diagnostic biomarkers and explore why translation of biomarker research for patient benefit has thus far failed. The authors also review recent progress and highlight advances in the understanding of the biology of pancreatic cancer that may lead to improvements in biomarker detection and implementation.
Department of Molecular and Clinical Cancer Medicine, National Institute for Health Research Liverpool Pancreas Biomedical Research Unit, University of Liverpool, Daulby Street, Liverpool L69 3GA, UK.
Claire
C
Jenkinson
Julie
J
Earl
Paula
P
Ghaneh
Christopher
C
Halloran
Alfredo
A
Carrato
William
W
Greenhalf
John
J
Neoptolemos
Eithne
E
Costello
D000230:Adenocarcinoma / Q000097:blood* / Q000737:chemistry / Q000175:diagnosis*; D001323:Autoantibodies / Q000097:blood; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood; D016207:Cytokines / Q000097:blood; D004273:DNA, Neoplasm / Q000097:blood; D055088:Early Detection of Cancer; D006801:Humans; D035683:MicroRNAs / Q000097:blood; D009360:Neoplastic Cells, Circulating; D010189:Pancreatic Juice / Q000737:chemistry; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000737:chemistry / Q000175:diagnosis*; D012333:RNA, Messenger / Q000032:analysis; D012463:Saliva / Q000737:chemistry; D057170:Translational Research, Biomedical
D001323:Autoantibodies; D014408:Biomarkers, Tumor; D016207:Cytokines; D004273:DNA, Neoplasm; D035683:MicroRNAs; D012333:RNA, Messenger
biomarker; diagnosis; jaundice; pancreatic cancer